Liver Cirrhosis: cell-therapy evidence by therapy class
Across every stem-cell intervention, ClinicalTrials.gov holds 89 registered records for Liver Cirrhosis — 6 recruiting, 7 at Phase 3 or 4, in 19 countries. Snapshot 2026-08-29.
The condition, and why cells are proposed
In cirrhosis, functioning liver tissue has been replaced by scar, and portal pressure rises as a result. Cell therapy is studied for anti-fibrotic and regenerative support, usually as a bridge rather than a substitute for transplantation. The liver's genuine regenerative capacity makes the rationale more biologically plausible here than in most indications — which is not the same as effective.
Therapy classes side by side
Counts come from separate registry queries per class; a study testing two interventions can appear in more than one row, so rows do not sum to the all-interventions total.
Geography of the research
China accounts for about 54% of country mentions among sampled studies; 19 countries host at least one site.
| Country | Studies with a site there |
|---|---|
| China | 38 |
| Iran | 6 |
| Vietnam | 4 |
| South Korea | 4 |
| Turkey (Türkiye) | 4 |
| Japan | 3 |
| Indonesia | 3 |
| Singapore | 3 |
The largest registered studies
Sorted by planned enrolment — size is not quality, but a 300-participant trial can answer questions a 12-participant series cannot.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT05080465 — Long Term Follow up Mesenchymal Stem Cell Therapy for Patients Virus-related Liver Cirrhosis | Phase 3 | Completed | 700 | Ukraine Association of Biobank | 2018-12-02 |
| NCT07028112 — Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantati | n/a | Recruiting | 500 | Assistance Publique - Hôpitaux de Paris | 2025-08-20 |
| NCT01573923 — Safety and Efficacy Study of Umbilical Mesenchymal Stem Cells for Liver Cirrhosis | Phase 1, Phase 2 | Unknown | 320 | Alliancells Bioscience Corporation Limited | 2014-07 |
| NCT01756794 — Validation of the Procedure of Early Liver Transplantation in Alcoholic Hepatitis Resisting to Medical Treatment | n/a | Completed | 284 | University Hospital, Lille | 2012-12-05 |
| NCT01220492 — Umbilical Cord Mesenchymal Stem Cells for Patients With Liver Cirrhosis | Phase 1, Phase 2 | Completed | 266 | Beijing 302 Hospital | 2009-05 |
| NCT02540382 — Comparison of Covered and Bare Stent in TIPS | n/a | Completed | 258 | Beijing Shijitan Hospital, Capital Medical University | 2006-01 |
Most recently registered
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07472270 — Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment | n/a | Not Yet Recruiting | n/a | Vinmec Research Institute of Stem Cell and Gene Technology | 2026-03-15 |
| NCT06984497 — Human Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD | n/a | Not Yet Recruiting | n/a | General Hospital of Shenyang Military Region | 2025-09 |
| NCT07028112 — Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantati | n/a | Recruiting | n/a | Assistance Publique - Hôpitaux de Paris | 2025-08-20 |
| NCT07011199 — Clinical Outcomes of Early Kasai Surgery With Umbilical Cord MSCs in Biliary Atresia | n/a | Not Yet Recruiting | n/a | Universitas Diponegoro | 2025-06-17 |
| NCT07413549 — Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis | n/a | Recruiting | n/a | Beijing Tuohua Weiye Biotechnology Co., Ltd. | 2025-02-25 |
Reading this honestly
These figures describe effort, not outcome. Published results, with their control arms and endpoints, are where benefit is decided. For Liver Cirrhosis specifically, the practical question is which registered study — if any — matches the product a provider is offering, and what its outcome measures actually are.
Frequently asked
How many stem-cell trials exist for Liver Cirrhosis?
89 registered records mention a stem-cell intervention for this condition (2026-08-29 snapshot), of which 6 were recruiting.
Which therapy class is furthest along for Liver Cirrhosis?
Ranked by Phase 3/4 records: MSC (4), HSCT (3), exosomes (0), PRP (0).
Does a recruiting trial mean I can be treated?
No. Trials have eligibility criteria, and joining one is not the same as buying a treatment. Paying a clinic for an unproven intervention outside a registered study gives you neither the protections nor the data collection of a trial.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.